Inhibrx Biosciences Inc (INBX) AI Stock Analysis

• Market Cap: $171.97M
• Dividend Yield: N/A
• Average Volume (3M): 132.91K
• Price to Earnings (P/E): 0.1
• Beta (1Y): 0.38
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 156
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): 116.58
• Shares Outstanding: 14,475,904
• 10 Day Avg. Volume: 200,807
• 30 Day Avg. Volume: 132,907
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 141.50
• Price to Cash Flow (P/CF): -1.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

Inhibrx Biosciences Inc. has significant financial challenges, with weak revenue generation and high leverage. Despite these issues, the company benefits from recent positive trial results and a substantial loan securing growth potential. While its valuation suggests it may be undervalued, the current technical indicators show a bearish trend. Overall, the stock's score reflects a high-risk profile with potential for upside if operational and financial improvements are realized.

Positive Factors

Clinical Trial Results

The ozekibart Phase 1 trial showed a 40% overall response rate, including complete and partial responses.

Financial Stability

Inhibrx is well-capitalized with $196.3 million in cash, allowing continued development of its drug candidates, including ozekibart.

Regulatory Progress

Ozekibart's registrational path in chondrosarcoma is progressing with enrollment of the Phase 2 pivotal trial, with the FDA giving the green light for a registrational study.

Negative Factors

Adverse Events

The treatment with ozekibart led to 1 treatment discontinuation and 3 dose-interruptions, and 1 patient passed away due to neutropenic sepsis.

Safety Concerns

Safety concerns are highlighted by a 31% ALT increase and a patient's death due to neutropenic sepsis.

Side Effects

The safety profile may limit the use of the combination treatment due to the potential for severe side effects.

Inhibrx Biosciences Inc Business Overview & Revenue Model

Company Description

Inhibrx Biosciences Inc (INBX) is a clinical-stage biopharmaceutical company that focuses on developing a pipeline of novel biologic therapeutic candidates. Its primary sectors include biotechnology and pharmaceuticals, with a strong emphasis on oncology, rare diseases, and infectious diseases. The company's core products are monoclonal antibodies designed to target validated but difficult-to-drug targets in these areas.

How the Company Makes Money

Inhibrx Biosciences Inc generates revenue primarily through strategic partnerships, licensing agreements, and collaborations with larger pharmaceutical companies. These partnerships typically involve upfront payments, milestone payments based on the achievement of specific development, regulatory, and commercial goals, and royalty payments on sales of products that arise from the collaborations. Additionally, the company may receive funding from governmental and non-governmental grants to support its research and development activities. Inhibrx's business model relies heavily on the successful progression of its drug candidates through clinical trials, which can then attract further investment and partnership opportunities.

Inhibrx Biosciences Inc Financial Statement Overview

Summary

Inhibrx Biosciences Inc presents a mixed financial picture with significant operational challenges. The income statement highlights issues with revenue generation and profitability, while the balance sheet indicates high leverage and potential solvency risks. Cash flow issues further exacerbate these concerns, despite some external financing support. Overall, the company needs to address these challenges to achieve a more stable financial footing.

Income Statement

Inhibrx Biosciences Inc has faced significant challenges in revenue generation, with a decline from previous years and a negative EBIT and EBITDA margin indicating operational inefficiencies. Although there is a notable spike in net income for 2024, this appears to be an anomaly and not reflective of consistent profitability. Overall, the company struggles with achieving a sustainable revenue growth trajectory.

Balance Sheet

The company has shown some improvement in stockholders' equity, yet it remains heavily leveraged with a debt-to-equity ratio indicating high financial risk. The equity ratio is low, suggesting that the company relies significantly on debt financing, which could be risky if revenue does not improve. The high liabilities relative to assets further highlight potential solvency concerns.

Cash Flow

Operating cash flows are consistently negative, reflecting ongoing operational challenges. The free cash flow position is also negative, indicating limited internal generation of cash for reinvestment or debt repayment. However, the company has managed to secure external financing, which has supported liquidity but raises concerns about long-term financial sustainability.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
200.00K	1.80M	2.18M	7.13M	12.81M
	Gross Profit
200.00K	609.00K	-668.00K	4.44M	-60.69M
	EBIT
-331.45M	-219.22M	-129.12M	-76.56M	-67.44M
	EBITDA
1.70B	-206.69M	-125.82M	-76.56M	-67.44M
	Net Income Common Stockholders
1.69B	-241.36M	-145.23M	-81.77M	-75.64M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
152.60M	277.92M	273.87M	131.30M	128.66M
	Total Assets
180.77M	307.89M	290.88M	150.45M	143.74M
	Total Debt
8.05M	210.14M	202.07M	70.47M	37.45M
	Net Debt
-144.55M	-67.78M	-71.80M	-60.83M	-91.21M
	Total Liabilities
47.18M	264.39M	232.82M	98.07M	68.27M
	Stockholders Equity
133.58M	43.50M	58.06M	52.38M	75.47M
Cash Flow		Free Cash Flow
-197.01M	-197.90M	-115.99M	-81.19M	-49.33M
	Operating Cash Flow
-194.41M	-193.31M	-115.30M	-80.32M	-47.97M
	Investing Cash Flow
-2.60M	-4.59M	-686.00K	-809.00K	-1.36M
	Financing Cash Flow
71.68M	201.96M	258.55M	83.77M	166.46M

Inhibrx Biosciences Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.88
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBX, the sentiment is Negative. The current price of 11.88 is below the 20-day moving average (MA) of 13.39, below the 50-day MA of 13.26, and below the 200-day MA of 14.21, indicating a bearish trend. The MACD of -0.52 indicates Positive momentum. The RSI at 37.74 is Neutral, neither overbought nor oversold. The STOCH value of 22.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INBX.

Inhibrx Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$3.93B	-17.35	-15.99%	6.44%	25.52%	-80.16%
MGX	45 Neutral	$56.82M	―	-34.69%	―	16.84%	57.38%
INBX	42 Neutral	$171.97M	0.10	919.96%	―	―	―
KYTX	38 Underperform	$96.37M	―	-80.74%	―	―	―
CTNM	34 Underperform	$103.23M	―	-64.95%	―	-100.00%	-244.85%
ANRO	30 Underperform	$57.66M	―	-153.99%	―	―	―
FBLG	23 Underperform	$36.98M	―	-559.73%	―	―	―

Inhibrx Biosciences Inc Corporate Events

Inhibrx Biosciences Appoints New President Amid Leadership Changes

On April 1, 2025, Inhibrx Biosciences, Inc. announced the appointment of David J. Matly as President, effective immediately, while he continues his role as Chief Commercial and Business Development Officer. This strategic move is expected to leverage Matly’s extensive experience in commercial launch and business development, enhancing the company’s market position. Concurrently, Brendan P. Eckelman resigned as Chief Scientific Officer on March 31, 2025, to establish a new private biotechnology company, marking a significant shift in the company’s leadership dynamics.

Inhibrx Biosciences Reports Promising Trial Results for INBRX-109

On January 21, 2025, Inhibrx Biosciences announced preliminary results from a Phase 1 trial of their therapeutic candidate ozekibart (INBRX-109) in combination with FOLFIRI for treating advanced colorectal adenocarcinoma. The trial showed promising efficacy, with one complete response and three partial responses among patients, and manageable safety profiles where most adverse events were low-grade. Encouraged by these results, Inhibrx has initiated an expansion cohort to further validate the findings, with results expected in the third quarter of 2025. This development underscores ozekibart’s potential in providing clinical benefits in heavily pretreated populations, positioning Inhibrx as an emerging player in the oncology therapeutics landscape.